# Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

> **NCT04462445** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT04462445
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-25
- **Primary completion:** 2017-02-08
- **Final completion:** 2017-02-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462445, "Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04462445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*